Animesh D Pardanani (Animesh Pardanani)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 66

Top Topics

Combination Therapy

Acute Myeloid Leukemia

Newly Diagnosed

Top Venues

American journal of hematology

British journal of haematology

Journal of thrombosis and haemostasis : JTH

This page only lists publications with an associated author ORCID identifier.

Publications

Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. American journal of hematology 99 (2) (2024)
Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref A Al-Kali, Hassan B Alkhateeb, Kebede Begna, Mark Litzow, William J Hogan, Mithun Vinod Shah, Mrinal M Patnaik, Animesh D Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology 204 (4) (2024)
Naseema Gangat, Amritpal Singh, Rimal Ilyas, Giuseppe Gaetano Loscocco, Michelle A Elliott, Kebede H Begna, Animesh D Pardanani, Ayalew Tefferi
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies. American journal of hematology (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? American journal of hematology (2024)
Naseema Gangat, Ellen McPhail, Kaaren Reichard, Attilio Orazi, Animesh D Pardanani, Ayalew Tefferi
Incidental discovery of KIT-mutated mastocytoma in a colon polyp. American journal of hematology 99 (5) (2024)
Xi Zhang, Yi Ding, Peng Li, Kirk Bourgeois, Aruna Rangan, Jennifer L Herrick, Animesh D Pardanani, Dong Chen, David Viswanatha, Rong He, Gang Zheng
Null-type SH2B3 mutations are potential drivers in a subset of Ph-negative myeloproliferative neoplasms. American journal of hematology 99 (9) (2024)
Naseema Gangat, Ellen McPhail, Kaaren Reichard, Attilio Orazi, Animesh D Pardanani, Ayalew Tefferi
Incidental discovery of KIT-mutated mastocytoma in a colon polyp. American journal of hematology 99 (5) (2024)
Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref A Al-Kali, Hassan B Alkhateeb, Kebede Begna, Mark Litzow, William J Hogan, Mithun Vinod Shah, Mrinal M Patnaik, Animesh D Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology 204 (4) (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. American journal of hematology 99 (2) (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. American journal of hematology (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? American journal of hematology 99 (8) (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? American journal of hematology 99 (8) (2024)
Naseema Gangat, Ellen McPhail, Kaaren Reichard, Attilio Orazi, Animesh D Pardanani, Ayalew Tefferi
Incidental discovery of KIT-mutated mastocytoma in a colon polyp. American journal of hematology (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. American journal of hematology 99 (2) (2024)
Xi Zhang, Yi Ding, Peng Li, Kirk Bourgeois, Aruna Rangan, Jennifer L Herrick, Animesh D Pardanani, Dong Chen, David Viswanatha, Rong He, Gang Zheng
Null-type SH2B3 mutations are potential drivers in a subset of Ph-negative myeloproliferative neoplasms. American journal of hematology (2024)
Naseema Gangat, Ellen McPhail, Kaaren Reichard, Attilio Orazi, Animesh D Pardanani, Ayalew Tefferi
Incidental discovery of KIT-mutated mastocytoma in a colon polyp. American journal of hematology 99 (5) (2024)
Ayalew Tefferi, Animesh D Pardanani, Naseema Gangat
Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? American journal of hematology 99 (8) (2024)
Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref A Al-Kali, Hassan B Alkhateeb, Kebede Begna, Mark Litzow, William J Hogan, Mithun Vinod Shah, Mrinal M Patnaik, Animesh D Pardanani, Joerg Hermann, Ayalew Tefferi, Naseema Gangat
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. British journal of haematology (2024)
Ayalew Tefferi, Animesh D Pardanani, Aref A Al-Kali, Hassan Alkhateeb, McCullough Kristen, Mirinal S Patnaik, William J Hogan, Kebede H Begna, Michelle A Elliott, Nandita Khera, Jeanne M Palmer, Naseema Gangat, Katalin Kelemen, Attilio Orazi, Dong Chen, Kaaren K Reichard
Mast cell cytomorphology and treatment outcome in mast cell leukemia. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Ayalew Tefferi, Maymona Abdelmagid, Aref A Al-Kali, Mirinal S Patnaik, William J Hogan, Kebede H Begna, Naseema Gangat, Attilio Orazi, Dong Chen, Kaaren K Reichard, Animesh D Pardanani
Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. American journal of hematology (2023)
Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref A Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al Ali, Eric Padron, David A Sallman, Mithun Vinod Shah, Devendra K Hiwase, Animesh D Pardanani, Daniel A Arber, Attilio Orazi, Kaaren K Reichard, Rong He, Rhett P Ketterling, Naseema Gangat, Rami S Komrokji, Ayalew Tefferi
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): a Mayo-Moffitt study of 156 informative cases. American journal of hematology (2023)
Animesh D Pardanani, Kaaren Reichard, Ayalew Tefferi
Advanced systemic mastocytosis-Revised classification, new drugs and how we treat. British journal of haematology (2023)
Naseema Gangat, Omer S Karrar, Moazah Iftikhar, McCullough Kristen, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. American journal of hematology (2023)
Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref A Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al Ali, Eric Padron, David A Sallman, Mithun Vinod Shah, Devendra K Hiwase, Animesh D Pardanani, Daniel A Arber, Attilio Orazi, Kaaren K Reichard, Rong He, Rhett P Ketterling, Naseema Gangat, Rami S Komrokji, Ayalew Tefferi
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. American journal of hematology (2023)
John McGlothlin, Jithma Abeykoon, Eyad Al-Hattab, Aneel A Ashrani, Michelle A Elliott, C Christopher Hook, Animesh D Pardanani, Rajiv Pruthi, Meera Sridharan, Alexandra Wolanskyj, Rachelle Rouse, Ronald Go
Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H Al Ali, Aref A Al-Kali, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Mithun Vinod Shah, Devendra K Hiwase, Eric Padron, David A Sallman, Animesh D Pardanani, Daniel A Arber, Attilio Orazi, Kaaren K Reichard, Rong He, Rhett P Ketterling, Naseema Gangat, Rami S Komrokji
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). British journal of haematology (2023)
Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, Natasha Szuber, Francesco Mannelli, Animesh D Pardanani, Curtis A Hanson, Rhett P Ketterling, Valerio De Stefano, Alessandra Carobbio, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro Maria Maria Vannucchi
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count. American journal of hematology (2023)
Animesh D Pardanani
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. American journal of hematology 98 (7) (2023)
Ahmad Nanaa, Rong He, James M Foran, Talha Badar, Naseema Gangat, Animesh D Pardanani, William J Hogan, Mark R Litzow, Mrinal Patnaik, Aref A Al-Kali, Hassan B Alkhateeb
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. British journal of haematology (2023)
Naseema Gangat, Mostafa Abdallah, Natasha Szuber, Antoine N Saliba, Hassan Alkhateeb, Aref A Al-Kali, Kebede H Begna, Animesh D Pardanani, Ayalew Tefferi
Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. American journal of hematology (2023)
Animesh D Pardanani, Ayalew Tefferi, Aref A Al-Kali, Mirinal S Patnaik, William J Hogan, Kebede H Begna, Michelle A Elliott, Nandita Khera, Jeanne M Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K Reichard, Dong Chen
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology (2023)
Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref A Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al Ali, Eric Padron, David A Sallman, Mithun Vinod Shah, Devendra K Hiwase, Animesh D Pardanani, Daniel A Arber, Attilio Orazi, Kaaren K Reichard, Rong He, Rhett P Ketterling, Naseema Gangat, Rami S Komrokji, Ayalew Tefferi
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. American journal of hematology 98 (4) (2023)
Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref A Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al Ali, Eric Padron, David A Sallman, Mithun Vinod Shah, Devendra K Hiwase, Animesh D Pardanani, Daniel A Arber, Attilio Orazi, Kaaren K Reichard, Rong He, Rhett P Ketterling, Naseema Gangat, Rami S Komrokji, Ayalew Tefferi
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. American journal of hematology 98 (4) (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref A Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al Ali, Eric Padron, David A Sallman, Mithun Vinod Shah, Devendra K Hiwase, Animesh D Pardanani, Daniel A Arber, Attilio Orazi, Kaaren K Reichard, Rong He, Rhett P Ketterling, Naseema Gangat, Rami S Komrokji, Ayalew Tefferi
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. American journal of hematology 98 (4) (2023)
Naseema Gangat, Kebede H Begna, Aref A Al-Kali, William Hogan, Mark R Litzow, Animesh D Pardanani, Ayalew Tefferi
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. American journal of hematology (2022)
Ayalew Tefferi, Naseema Gangat, Animesh D Pardanani
Jaktinib (JAK1/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule. American journal of hematology 97 (12) (2022)
Ayalew Tefferi, Animesh D Pardanani, Kebede H Begna, Aref A Al-Kali, William J Hogan, Mark R Litzow, Curtis A Hanson, Rhett P Ketterling, Naseema Gangat
Momelotinib for myelofibrosis: 12-year survival data and retrospective comparison to ruxolitinib. American journal of hematology 97 (12) (2022)
Abhishek A Mangaonkar, Faiqa Farrukh, Kaaren K Reichard, Rhett P Ketterling, Naseema Gangat, Aref Al-Kali, Kebede H Begna, Animesh D Pardanani, Mirinal S Patnaik, Ayalew Tefferi
Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T. American journal of hematology 97 (3) (2022)
Naseema Gangat, Kristen McCullough, Aref A Al-Kali, Kebede H Begna, Mrinal M Patnaik, Mark R Litzow, William Hogan, Mithun Vinod Shah, Hassan Alkhateeb, Abhishek A Mangaonkar, James M Foran, Jeanne M Palmer, Animesh D Pardanani, Ayalew Tefferi
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. British journal of haematology 198 (4) (2022)
Naseema Gangat, McCullough Kristen, Isla Johnson, Aref Al-Kali, Kebede H Begna, Mirinal S Patnaik, Mark R Litzow, William Hogan, Mithun Vinod Shah, Hassan Alkhateeb, Abhishek A Mangaonkar, James M Foran, Talha Badar, Jeanne M Palmer, Lisa Sproat, Cecilia Y Arana Yi, Animesh D Pardanani, Ayalew Tefferi
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American journal of hematology 97 (6) (2022)
Naseema Gangat, Deandra Chetram, McCullough Kristen, Aref A Al-Kali, Kebede H Begna, William Hogan, Mark R Litzow, James Foran, Talha Badar, Jeanne Palmer, Mirinal S Patnaik, Animesh D Pardanani, Ayalew Tefferi
Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts. American journal of hematology 97 (12) (2022)
Amritpal Singh, Aref A Al-Kali, James M Foran, Michelle A Elliott, Kebede H Begna, Talha Badar, Nandita Khera, Farah Fleti, Maymona Abdelmagid, Kareen K Reichard, Rhett P Ketterling, Animesh D Pardanani, Naseema Gangat, Ayalew Tefferi
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting. American journal of hematology 97 (10) (2022)
Amritpal Singh, Hassan Alkhateeb, Animesh D Pardanani, Rong He, Attilio Orazi, Ayalew Tefferi, Kaaren K Reichard
Mast cell sarcoma: 2 Mayo Clinic cases. American journal of hematology 97 (10) (2022)
Faiqa Farrukh, Naseema Gangat, Mithun Vinod Shah, Mark R Litzow, Michelle A Elliott, Kebede H Begna, Christopher C Hook, Ayalew Tefferi, Animesh D Pardanani
Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience. American journal of hematology 97 (4) (2022)
Ayalew Tefferi, Naseema Gangat, Aref Al-Kali, Hassan Alkhateeb, Mithun Vinod Shah, Mirinal S Patnaik, Michelle A Elliott, William J Hogan, Mark R Litzow, Christopher C Hook, Abhishek A Mangaonkar, David Viswanatha, Dong Chen, Animesh D Pardanani, Rhett P Ketterling, Courtney D D DiNardo, Tapan Mahendra Kadia, Farhad Ravandi, Koji Sasaki, Kebede H Begna
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American journal of hematology 97 (9) (2022)
Naseema Gangat, Amritpal Singh, Natasha Szuber, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Curtis A Hanson, Animesh D Pardanani, Valerio De Stefano, Tiziano Barbui, Alessandro Maria Maria Vannucchi, Ayalew Tefferi
Site-specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival. Journal of thrombosis and haemostasis : JTH 20 (10) (2022)
Amritpal Singh, Aref Al-Kali, Kebede H Begna, Mark R Litzow, Jeremy T Larsen, Taimur Sher, Maymona G Abdelmagid, Faiqa Farrukh, Kaaren K Reichard, Naseema Gangat, Animesh D Pardanani, Ayalew Tefferi
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. American journal of hematology 97 (5) (2022)
Gaurav Goyal, Jithma A Abeykoon, Marie Hu, Jason R Young, Mithun V Shah, N Nora Bennani, Timothy G Call, C Christopher Hook, Animesh D Pardanani, David J Inwards, Robert Vassallo, Jay H Ryu, W Oliver Tobin, Matthew J Koster, Caroline J Davidge-Pitts, Aishwarya Ravindran, Karen L Rech, Ronald S Go, null null
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. American journal of hematology 96 (5) (2021)
Naseema Gangat, Jennifer L Oliveira, James D Hoyer, Mirinal S Patnaik, Animesh D Pardanani, Ayalew Tefferi
High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. American journal of hematology 96 (12) (2021)
Ayalew Tefferi, Jaya Kittur, Faiqa Farrukh, Kebede H Begna, Mrinal M Patnaik, Aref A Al-Kali, Michelle A Elliott, Kaaren K Reichard, Naseema Gangat, Animesh D Pardanani
Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. British journal of haematology (2021)
Giuseppe Gaetano Loscocco, Paola Guglielmelli, Naseema Gangat, Elena Rossi, Carmela Mannarelli, Silvia Betti, Chiara Maccari, Francesco Ramundo, Yamna Jadoon, Francesca Gesullo, Sara Ceglie, Chiara Paoli, Animesh D Pardanani, Valerio De Stefano, Ayalew Tefferi, Alessandro Maria Maria Vannucchi
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American journal of hematology 96 (11) (2021)
Kebede H Begna, Naseema Gangat, Aref Al-Kali, Mark R Litzow, William J Hogan, Mirinal S Patnaik, Animesh D Pardanani, C Christopher Hook, Alexandra P Wolanskyj, Michelle A Elliott, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy. American journal of hematology 96 (4) (2021)
Ayalew Tefferi, Natasha Szuber, Animesh D Pardanani, Curtis A Hanson, Alessandro Maria Maria Vannucchi, Tiziano Barbui, Naseema Gangat
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American journal of hematology 96 (6) (2021)
Faiqa Farrukh, Paola Guglielmelli, Giuseppe Gaetano Loscocco, Animesh D Pardanani, Curtis A Hanson, Valerio De Stefano, Tiziano Barbui, Naseema Gangat, Alessandro Maria Maria Vannucchi, Ayalew Tefferi
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American journal of hematology (2021)
Naseema Gangat, Paola Guglielmelli, Aref A Al-Kali, Alexandra P Wolanskyj-Spinner, John Camoriano, Mrinal M Patnaik, Animesh D Pardanani, Curtis A Hanson, Alessandro M Vannucchi, Ayalew Tefferi
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. British journal of haematology 195 (1) (2021)
Animesh D Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko, Mark Drummond, Eric Jourdan, Alessandro Vannucchi, Mindaugas Jurgutis, Vincent Ribrag, Alessandro Rambaldi, Liang Piu Koh, Shelonitda Rose, Jun Zhang, Claire Harrison
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. British journal of haematology 195 (2) (2021)
Kebede H Begna, Jaya Kittur, Jennifer Yui, Naseema Gangat, Mrinal M Patnaik, Aref A Al-Kali, Michelle A Elliott, William J Hogan, Mark R Litzow, Christopher C Hook, Alexandra P Wolanskyj, Matthew T Howard, Curtis A Hanson, Rhett P Ketterling, Animesh D Pardanani, Ayalew Tefferi
De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British journal of haematology 195 (3) (2021)
Animesh D Pardanani
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. American journal of hematology 96 (4) (2021)
Caleb J Smith, John W Thomas, Gordon J Ruan, Meredith C Hyun, Radhika Bansal, Nicole R McLaughlin, Animesh D Pardanani, Naseema Gangat, Ronald S Go, Natasha Szuber, Gaurav Goyal, Mithun Vinod Shah, Ayalew Tefferi
A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American journal of hematology 96 (12) (2021)
Naseema Gangat, Paola Guglielmelli, Natasha Szuber, Kebede H Begna, Mirinal S Patnaik, Mark R Litzow, Aref Al-Kali, James M Foran, Jeanne M Palmer, Hassan Alkhateeb, Michelle A Elliott, Curtis A Hanson, Animesh D Pardanani, Francesco Mannelli, Alessandro Maria Maria Vannucchi, Ayalew Tefferi
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American journal of hematology 96 (7) (2021)
Naseema Gangat, Natasha Szuber, Tabinda Jawaid, Curtis A Hanson, Animesh D Pardanani, Ayalew Tefferi
Young platelet millionaires with essential thrombocythemia. American journal of hematology 96 (4) (2021)
Animesh D Pardanani, Ayalew Tefferi
How I treat myelofibrosis after failure of JAK inhibitors. Blood 132 (5) (2018)